Silexion Therapeutics Corp (SLXN)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Silexion Therapeutics Corp has not issued a press release in this window.
SEC filings
All filings →Silexion Therapeutics Corp has not filed an SEC document in this window.
Insider trades
All insider trades →Silexion Therapeutics Corp has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Silexion Therapeutics Corp in this window.
People at Silexion Therapeutics Corp
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for Silexion Therapeutics Corp.